4.5 Review

The association between rheumatoid arthritis and periodontal disease

期刊

ARTHRITIS RESEARCH & THERAPY
卷 12, 期 5, 页码 -

出版社

BMC
DOI: 10.1186/ar3106

关键词

-

向作者/读者索取更多资源

Chronic, plaque-associated inflammation of the gingiva and the periodontium are among the most common oral diseases. Periodontitis (PD) is characterized by the inflammatory destruction of the periodontal attachment and alveolar bone, and its clinical appearance can be influenced by congenital as well as acquired factors. The existence of a rheumatic or other inflammatory systemic disease may promote PD in both its emergence and progress. However, there is evidence that PD maintains systemic diseases. Nevertheless, many mechanisms in the pathogenesis have not yet been examined sufficiently, so that a final explanatory model is still under discussion, and we hereby present arguments in favor of this. In this review, we also discuss in detail the fact that oral bacterial infections and inflammation seem to be linked directly to the etiopathogenesis of rheumatoid arthritis (RA). There are findings that support the hypothesis that oral infections play a role in RA pathogenesis. Of special importance are the impact of periodontal pathogens, such as Porphyromonas gingivalis on citrullination, and the association of PD in RA patients with seropositivity toward rheumatoid factor and the anti-cyclic citrullinated peptide antibody.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Rheumatology

Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial

Maarten Boers, Linda Hartman, Daniela Opris-Belinski, Reinhard Bos, Marc R. Kok, Jose A. P. Da Silva, Eduard N. Griep, Ruth Klaasen, Cornelia F. Allaart, Paul Baudoin, Hennie G. Raterman, Zoltan Szekanecz, Frank Buttgereit, Pavol Masaryk, L. Thomas Klausch, Sabrina Paolino, Annemarie M. Schilder, Willem F. Lems, Maurizio Cutolo

Summary: This study compared the effects and side effects of low-dose prednisolone and placebo treatment in elderly patients with active rheumatoid arthritis. The results showed that low-dose prednisolone can reduce disease activity and joint damage, but the side effects also increased by 24%.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Review Rheumatology

Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritis

Lotte van Ouwerkerk, Andriko Palmowski, Isabell S. Nevins, Frank Buttgereit, Patrick Verschueren, Josef S. Smolen, Robert B. M. Landewe, Johannes J. W. Bijlsma, Andreas Kerschbaumer, Rene Westhovens, Tom W. J. Huizinga, Cornelia F. Allaart, Sytske Anne Bergstra

Summary: Studies on the success rate of glucocorticoid discontinuation in newly diagnosed rheumatoid arthritis patients using temporary GC as initial therapy are limited. Most clinical trials showed a successful discontinuation rate of 78% at 12 months and 90% at 24 months, despite substantial heterogeneity.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Review Rheumatology

The safety of glucocorticoids in the treatment of inflammatory rheumatic disease: new evidence

Mariana Luis, Maarten Boers, Ken Saag, Frank Buttgereit, Jose A. P. da Silva

Summary: Glucocorticoids are still considered a cornerstone in the treatment of inflammatory rheumatic diseases, despite the known dose-dependent side effects. However, there is currently limited solid evidence regarding the safety of low-dose glucocorticoids.

CURRENT OPINION IN RHEUMATOLOGY (2022)

Article Rheumatology

Development of prediction models to select older RA patients with comorbidities for treatment with chronic low-dose glucocorticoids

Linda Hartman, Jose A. P. da Silva, Frank Buttgereit, Maurizio Cutolo, Daniela Opris-Belinski, Zoltan Szekanecz, Pavol Masaryk, Marieke J. H. Voshaar, Martijn W. Heymans, Willem F. Lems, Desiree M. F. M. van der Heijde, Maarten Boers

Summary: This study aims to develop prediction models for individual harm and benefit outcomes in elderly RA patients treated with low-dose glucocorticoid therapy. The results suggest that baseline factors have limited predictive value in determining the chance of benefit or harm.

RHEUMATOLOGY (2023)

Article Rheumatology

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

Josef S. Smolen, Robert B. M. Landewe, Sytske Anne Bergstra, Andreas Kerschbaumer, Alexandre Sepriano, Daniel Aletaha, Roberto Caporali, Christopher John Edwards, Kimme L. Hyrich, Janet E. Pope, Savia de Souza, Tanja A. Stamm, Tsutomu Takeuchi, Patrick Verschueren, Kevin L. Winthrop, Alejandro Balsa, Joan M. Bathon, Maya H. Buch, Gerd R. Burmester, Frank Buttgereit, Mario Humberto Cardiel, Katerina Chatzidionysiou, Catalin Codreanu, Maurizio Cutolo, Alfons A. den Broeder, Khadija El Aoufy, Axel Finckh, Joao Eurico Fonseca, Jacques-Eric Gottenberg, Espen A. Haavardsholm, Annamaria Iagnocco, Kim Lauper, Zhanguo Li, Iain B. McInnes, Eduardo F. Mysler, Peter Nash, Gyula Poor, Gorica G. Ristic, Felice Rivellese, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Nikolay Stoilov, Anja Strangfeld, Annette van der Helm-van Mil, Elsa van Duuren, Theodora P. M. Vliet Vlieland, Rene Westhovens, Desiree van der Heijde

Summary: This study provides an update on the management recommendations for rheumatoid arthritis (RA) based on the latest developments in the field. The recommendations cover various aspects including medication use, combination therapy, treatment strategies, and dose reduction. The consensus was reached on 5 overarching principles and 11 specific recommendations.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Letter Rheumatology

Optimizing the reporting and conduct of systematic literature reviews and meta-analyses

Zhivana Boyadzhieva, Sabrina Mai Nielsen, Frank Buttgereit, Robin Christensen, Andriko Palmowski

ZEITSCHRIFT FUR RHEUMATOLOGIE (2023)

Article Rheumatology

Efficacy and Safety of ABBV-3373, a Novel Anti-Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody-Drug Conjugate, in Adults with Moderate-to-Severe Rheumatoid Arthritis Despite Methotrexate Therapy: A Randomized, Double-Blind, Active-Controlled Proof-of-Concept Phase IIa Trial

Frank Buttgereit, Jacob Aelion, Bernadette Rojkovich, Anna Zubrzycka-Sienkiewicz, Su Chen, Yang Yang, Dilek Arikan, Ronilda D'Cunha, Yinuo Pang, Hartmut Kupper, Timothy Radstake, Howard Amital

Summary: This study aimed to assess the efficacy and safety of ABBV-3373, a novel antibody-drug conjugate (ADC), compared to adalimumab in patients with rheumatoid arthritis (RA). The results showed that ABBV-3373 had superior efficacy and safety compared to historical adalimumab, supporting its continued development for RA treatment.

ARTHRITIS & RHEUMATOLOGY (2023)

Editorial Material Rheumatology

Tocilizumab in Giant Cell Arteritis: Better Understanding the Benefits

Frank Buttgereit, Andriko Palmowski, Idil Esen, Elisabeth Brouwer

ARTHRITIS & RHEUMATOLOGY (2023)

Article Rheumatology

Points to consider: EULAR-UEMS standards for the training of European rheumatologists

Alessia Alunno, Tadej Avcin, Catherine Haines, Sofia Ramiro, Francisca Sivera, Sara Badreh, Xenofon Baraliakos, Johannes W. J. Bijlsma, Frank Buttgereit, Kaushik Chaudhuri, Jose A. P. Da Silva, Jean Dudler, Ricardo J. O. Ferreira, Tania Gudu, Eric Hachulla, Mette Holland-Fischer, Annamaria Iagnocco, Tue Wenzel Kragstrup, Gyoergy Nagy, Vasco C. Romao, Simon R. Stones, Marloes van Onna, Christopher J. Edwards

Summary: This study aimed to define competences and standards for the training of rheumatologists. Through collaboration and analysis of international training documents, an overall framework, 7 domains, 8 core themes, and 28 competences were established. The results suggest that these standards can contribute to harmonizing rheumatology training across European countries.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Review Rheumatology

Safety and efficacy associated with long-term low-dose glucocorticoids in rheumatoid arthritis: a systematic review and meta-analysis

Andriko Palmowski, Sabrina M. Nielsen, Zhivana Boyadzhieva, Abelina Schneider, Anne Pankow, Linda Hartman, Jose A. P. Da Silva, John Kirwan, Siegfried Wassenberg, Christian Dejaco, Robin Christensen, Maarten Boers, Frank Buttgereit

Summary: The study aimed to assess the safety and efficacy of long-term low-dose glucocorticoids in Rheumatoid Arthritis (RA). The analysis found that low-dose glucocorticoids did not increase the risk of adverse events, except for a higher risk of infections. It also showed moderate to high evidence of improvement in disease activity and function in RA.

RHEUMATOLOGY (2023)

Article Multidisciplinary Sciences

A buprenorphine depot formulation provides effective sustained post-surgical analgesia for 72 h in mouse femoral fracture models

Angelique Wolter, Christian H. Bucher, Sebastian Kurmies, Viktoria Schreiner, Frank Konietschke, Katharina Hohlbaum, Robert Klopfleisch, Max Loehning, Christa Thoene-Reineke, Frank Buttgereit, Joerg Huwyler, Paulin Jirkof, Anna E. Rapp, Annemarie Lang

Summary: In animal experiments, adequate pain management is necessary and should last for the expected pain period without repeated application. The current depot formulations of Buprenorphine have limited duration of action, but a new sustained-release formulation (BUP-Depot) has been developed as a potential alternative in Europe. It provides effective analgesia for 72 hours, similar to Tramadol in the drinking water.

SCIENTIFIC REPORTS (2023)

Article Immunology

Serum proteomics in giant cell arteritis in response to a three-day pulse of glucocorticoid followed by tocilizumab monotherapy (the GUSTO trial)

Lisa Christ, Andrea D. Gloor, Florian Kollert, Timo Gaber, Frank Buttgereit, Stephan Reichenbach, Peter M. Villiger

Summary: This study reported proteome analyses in patients with newly diagnosed, untreated giant cell arteritis (GCA), as well as the changes of protein expression upon treatment with glucocorticoids (GC) and/or tocilizumab (TCZ). The majority of protein changes occurred within 10 days of treatment initiation. GC and TCZ had differential effects on protein regulation. CCL7, CXCL9, and MMP12 are biomarkers reflecting disease activity.

FRONTIERS IN IMMUNOLOGY (2023)

Article Medicine, General & Internal

Characterizing Sjogren-Associated Fatigue: A Distinct Phenotype from ME/CFS

Laura Kim, Claudia Kedor, Frank Buttgereit, Harald Heidecke, Desiree Schaumburg, Carmen Scheibenbogen

Summary: Fatigue is a common and debilitating symptom in primary Sjogren's syndrome (pSS) patients. This study aimed to evaluate fatigue and other symptoms in pSS patients and investigate if there is symptom overlap with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The severity of pSS symptoms and disease activity were assessed, and hand grip strength (HGS) and autoantibody levels were measured. Some pSS patients experienced severe fatigue and exhibited higher levels of pain, depression, and sleep disturbances. Four out of eighteen pSS patients met the criteria for ME/CFS. HGS parameters correlated strongly with fatigue severity but fully recovered after exertion, unlike ME/CFS. Elevated levels of certain autoantibodies were associated with disease activity but not fatigue severity. Only a small subgroup of pSS patients fulfilled the criteria for ME/CFS, and post-exertional malaise was primarily triggered by mental/emotional exertion rather than physical exertion. HGS assessment is an objective measure for overall fatigue severity.

JOURNAL OF CLINICAL MEDICINE (2023)

Article Rheumatology

Sex and age do not modify the association between glucocorticoids and bone mineral density in patients with rheumatoid arthritis: a cross-sectional study

Andriko Palmowski, Zhivana Boyadzhieva, Sabrina M. Nielsen, Burkhard Muche, Sandra Hermann, Maarten Boers, Henning Bliddal, Robin Christensen, Edgar Wiebe, Frank Buttgereit

Summary: This study investigated whether the association between glucocorticoid (GC) use and reduced bone mineral density (BMD) in rheumatoid arthritis (RA) patients is modified by sex or age. The results showed no significant differences in the association between GC use and BMD reduction, regardless of sex or age.

ARTHRITIS RESEARCH & THERAPY (2023)

Article Rheumatology

No association between methotrexate and impaired bone mineral density in a cohort of patients with polymyalgia rheumatica, giant cell arteritis, granulomatosis with polyangiitis and other vasculitides-a cross-sectional analysis with dose-response analyses

Andriko Palmowski, Mitsuteru Akahoshi, Burkhard Muche, Zhivana Boyadzhieva, Sandra Hermann, Chikashi Terao, Edgar Wiebe, Frank Buttgereit

Summary: This study aimed to investigate the association between methotrexate (MTX) use and bone mineral density (BMD) in patients with polymyalgia rheumatica (PMR) and various forms of vasculitis. The results showed that there was no association between MTX use and BMD levels. This study is important for evaluating the use of MTX and its impact on BMD in patients with PMR and vasculitis.

RHEUMATOLOGY INTERNATIONAL (2023)

暂无数据